CHICAGO, June 1 (Reuters) - Drug development company Poniard Pharmaceuticals Inc (PARD.O: Quote, Profile, Research) reported promising preliminary trial results for a new type of chemotherapy on Sunday, findings it hopes will be strong enough to land a development partner to help finance future studies. "The ideal partner for us would be a single business with a global reach," Jerry McMahon, the company's chief executive, told Reuters.
